NCT02348424View on ClinicalTrials.gov

Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 5, 2015

Primary Completion Date

January 13, 2017

Study Completion Date

January 13, 2017

Conditions
Gonorrhoea
Interventions
DRUG

Solithromycin

Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.

Trial Locations (1)

21224-2735

Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02348424 - Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin | Biotech Hunter | Biotech Hunter